Creative Commons source reading · ALS and frontotemporal degeneration
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
Federico Verde; Markus Otto; Vincenzo Silani
Originally published in Frontiers in neuroscience · 2021-06-21
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related currently incurable neurodegenerative diseases. ALS is characterized by degeneration of upper and lower motor neurons causing relentless paralysis of voluntary muscles, whereas in FTD, progressive atrophy of the frontal and temporal lobes of the brain results in deterioration of cognitive functions, language, personality, and behavior. In contrast to Alzheimer's disease (AD), ALS and FTD still lack a specific neurochemical biomarker reflecting neuropathology ex vivo . However, in the past 10 years, considerable progress has been made in the characterization of neurofilament light chain (NFL) as cerebrospinal fluid (CSF) and blood biomarker for both diseases. NFL is a structural component of the axonal cytoskeleton and is released into the CSF as a consequence of axonal damage or degeneration, thus behaving in general as a relatively non-specific marker of neuroaxonal pathology.
Conclusion and Perspectives
A large body of evidence demonstrates that NFL is increased in the CSF and, consequently, in the blood, in both ALS and FTD in comparison with normal conditions (Scherling et al., 2014; Steinacker et al., 2016; Gille et al., 2019; Illán-Gala et al., 2021). In the case of ALS, the diagnostic potential of CSF and blood NFL is not much lower than that of the established CSF biomarkers for Alzheimer’s disease (Blennow et al., 2010; Steinacker et al., 2016; Verde et al., 2019b).
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
